CK Life Sciences published its FY2025 annual results, reporting a net loss attributable to shareholders of HKD 186.81 million and basic loss per share of 1.94 Hong Kong cents. Revenue fell 5.2% to HKD 5.41 billion, including a 5.4% decline in nutraceutical revenue to HKD 3.37 billion amid economic uncertainty and cost increases largely driven by tariffs. Other income, gains and losses more than doubled to HKD 379.55 million, including a HKD 693.92 million gain on disposal of subsidiaries. Bank borrowings totaled HKD 6.03 billion, while bank balances and time deposits were HKD 603.07 million. Management said a 2025 corporate reorganization aims to increase pharmaceuticals and diagnostics R&D intensity and open new funding sources, highlighted by the October transaction in which Nasdaq-listed TransCode acquired the late-stage melanoma vaccine seviprotimut-L, and said the board did not recommend a final dividend.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CK Life Sciences International (Holdings) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260317-12055912), on March 17, 2026, and is solely responsible for the information contained therein.